Key Highlights

  • Enlivex shares are trading down 20.22% at $1.42, against a previous close of $1.78.
  • Allocetra responder rate reached 79.2% versus 47.6% for placebo in patients aged 64 and older.
  • No treatment-related serious adverse events were observed through 12 months.

Enlivex (NASDAQ:ENLV) shares are trading down 20.22% at $1.42, against a previous close of $1.78, even after the company announced favorable 12-month topline data from the Phase IIa stage of its Allocetra trial in knee osteoarthritis. The stock trades below $5, which makes it a penny stock, and Volume stands at about 100,000 shares.

Enlivex, headquartered in Ness Ziona, Israel, is a clinical-stage macrophage reprogramming immunotherapy company founded in 2005. Its lead candidate, Allocetra, is an off-the-shelf allogeneic cell therapy designed to restore macrophages to their homeostatic state. The company is focused on late-stage development in knee osteoarthritis and is also advancing Allocetra-OTS for organ failure in sepsis.

What the 12-Month Data Show

The randomized, double-blind, placebo-controlled stage of the multi-country Phase I/IIa trial evaluated Allocetra in patients with moderate to severe knee osteoarthritis. A single three-injection treatment cycle produced a sustained response through one year in primary age-related knee osteoarthritis, the population in the company's ongoing Phase IIb trial.

In patients aged 64 and older, 79.2% of the Allocetra group achieved a clinically meaningful response, defined as reduced pain and improved knee function, against 47.6% for placebo at 12 months (p=0.027). That is a 66% higher responder rate. The benefit was consistent with earlier timepoints, which showed an 80% higher rate at three months (p=0.019) and a 39% higher rate at six months (p=0.168).

Patient age was the strongest predictor of response, and the treatment effect grew with age. The company said patient-reported outcomes were supported by objective physical performance tests and by exploratory serum biomarker and imaging analyses consistent with the proposed macrophage-reprogramming mechanism.

Pain, Function and Safety

On the WOMAC scale, which runs from 0 to 100, the difference versus placebo in pain change from baseline was minus 17.5 points at three months (p=0.004), minus 15.4 at six months (p=0.012) and minus 12.2 at 12 months (p=0.113). Function differences were minus 19.3, minus 19.5 and minus 13.1 points at the same timepoints, with p-values of 0.0008, 0.0008 and 0.067.

The 12-month pain and function differences still favored Allocetra but did not reach statistical significance in the 64 and older group, a detail that stands apart from the responder result. No treatment-related serious adverse events were observed, and adverse events were predominantly transient.

Next Steps and Market Reaction

Enlivex will present the one-year safety and efficacy results as a poster at the American College of Rheumatology Convergence on Nov. 8. The company noted that knee osteoarthritis has no approved disease-modifying therapies, with treatment largely limited to symptom management or surgery.

Enlivex describes itself as a quality longevity company powered by a prediction markets treasury, a positioning that sits alongside its clinical work. The company said the 12-month results show that a single treatment cycle delivered a clinically meaningful benefit in older patients, sustained through one year, in a disease with no approved disease-modifying therapies. A durable response from one cycle, it added, could offer a differentiated profile for patients, physicians and payers.

The sharp decline shows how a favorable headline can be weighed against the finer statistical detail in a small trial. Investors will look to the Phase IIb results to see whether the responder benefit holds in a larger group, and whether the pain and function gaps that narrowed by month 12 widen again.